AI-Designed Antibodies: Scientifically Sound, Commercially Doubtful
anshulkundaje · x · 2026-07-17
A long article on AI-designed antibodies, the author's core judgment:
- Scientifically, this direction is solid, not just another round of pure hype
- But commercially, whether it can become a good business remains questionable
The post relays a measured conclusion: he has experienced many similar "revolutionary" narratives; this time it's more like genuine scientific progress, but the commercialization path may not be equally smooth.
More from Companies & People
- Investor argues Palantir-Nvidia partnership should slash Anthropic's IPO valuation — pdamodaran · 2026-09-11
- PyTorch Day Korea 2026 launches first offline conf, CFP closes Sept 13 — PyTorch · 2026-09-11
- Class action accuses Anthropic of overselling Claude subscriptions with deceptive usage multipliers — The Decoder · 2026-09-11
- AI post-training and evals jobs pay up to $850K, with median offers at $210K–$325K — FinanceYF5 · 2026-09-11
- Only a 4-day window: timeline casts doubt on OpenAI's independent math result claim — gleech · 2026-09-11
- 89% of firms use AI, only 6% see significant ROI — the busywork illusion — mikeflache · 2026-09-11